ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Lung Cancer

Using Immune Checkpoint Inhibitors in Lung Cancer

Immune checkpoint inhibitors have changed the treatment paradigm for patients with lung cancer, bringing about the most promising outcomes we have seen in a long time.

Lung Cancer

Although the overall incidence of programmed cell death 1 (PD-1) inhibitor-related pneumonitis is rare, the serious adverse event may occur more commonly in certain solid tumor types like non–small-cell lung cancer and renal cell carcinoma.

Immune checkpoint inhibitors are a reality for the treatment of patients with NSCLC, and if approved for SCLC, would be a treatment breakthrough we have not seen for decades.

Immune checkpoint inhibitors have changed the treatment paradigm for patients with lung cancer, bringing about the most promising outcomes we have seen in a long time.

The combination of pemetrexed and gefitinib offered improved progression-free survival in East Asian patients with advanced nonsquamous NSCLC and activating EGFR mutations.

A trial showed that KRAS wild-type NSCLC patients fare better with regimens containing erlotinib, while KRAS-mutated patients had better outcomes without erlotinib.

ALK-targeting agents such as crizotinib may work most effectively in lung cancer patients with ALK variant 1.

In this article, we review the available literature addressing the competing treatment strategies in EGFR-Positive Lung Cancer and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.